https://orcid.org/0000-0002-2260-9277
References
- Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007;21:355–73.
- Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005;353: 1899–911.
- Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol 2008;74:4898–909.
- Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961–71.
- Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 2015;122:785–94.
- Sobel JD, Subramanian C, Foxman B, et al. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep 2013;15:104–8.
- Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73:1253–63.
- Bizzini B, Henocq E, Reynier J, Relyveld EH. Experimental and clinical results with the Corynebacterium granulosum-derived immunomodulator P40. Asian Pac J Allergy Immunol 1984;2:144–53.
- Pfefferle PI, Prescott SL, Kopp M. Microbial influence on tolerance and opportunities for intervention with prebiotics/probiotics and bacterial lysates. J Allergy Clin Immunol 2013;131:1453–63.
- Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med 2008;102:321–7.
- Collette JR, Zhou H, Lorenz MC. Candida albicans suppresses nitric oxide generation from macrophages via a secreted molecule. PLoS One 2014;9:e96203.
- Buck GE, Kelly MT. Investigation of the component of Propionibacterium acnes (Corynebacterium parvum) responsible for macrophage activation. Infect Immun 1980;27:620–7.
- Ohashi M, Amagai T, Ushijima T, et al. Mode of protection of mice against herpes simplex virus type 2 infection by Propionibacterium. Microbiol Immunol 1983;27:601–9.
- Henocq E, Veronesi R, Bazin JC, Bizzini B. Treatment of relapsing chronic infections of the respiratory tract. A comparative study of the effectiveness of non specific immunotherapy with the immunoadjuvant P40 and of vaccinotherapy. Rev Inst Med Trop Sao Paulo 1984; 26:105–9.
- Henocq E, Arvis G, Delsaux MC, Bizzini B. Traitment des infections urogenitales recidivantes par immunomodulation. Ann Urol (Paris) 1985;19:371–5.
- Grimaldi EF, Restaino S, Inglese S, et al. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. Minerva Ginecol 2012;64:321–9.
- Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet 2013;288:1199–201.
- Fiorilli A, Molteni B, Milani M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol 2005;120:202–5.
- Melis GB, Marotto MF, Orrù MM, et al. Bacterial vaginosis: efficacy of a local treatment with a gel containing a fraction derived from Propinibacterium acnes. Minerva Ginecol 2016;68:1–8.
- Melis GB, Marotto MF, Orrù MM, et al. Vulvo-vaginal candidiasis: efficacy of a local treatment with a gel containing a fraction- derived from Propinibacterium acnes in addition to fluconazole. MJWH 2013;2:39–43.
- Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22.
- Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004;191:1124–9.
- Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 2013;8:e74378.